Rheumatology Medical News about Juvenile Arthritis

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Anakinra for Systemic Juvenile Arthritis: The Rocky Mountain Experience
Journal of Clinical Rheumatology (JCR), 06/15/09

Zeft A et al. - Treatment with anakinra was associated with short-term improvements in large joint counts and laboratory parameters of active disease. Higher anakinra doses may be more efficacious in treating the systemic inflammatory response in systemic onset juvenile idiopathic arthritis patients. A subset of patients had periods of arthritis during treatment, and local side-effects were frequent. The experience supports the continued use of interleukin-1 inhibition in systemic juvenile arthritis and the search for more effective and more tolerable forms of interleukin-1 inhibition.

<< Previous
Identification of AF4/FMR2 family, member 3 (AFF3) as a novel...

Next >>
Psoriatic arthritis assessment and treatment update

New Study Detects No Invasive Cancer Risk in Juvenile Arthritis Patients
MedLinePlus, 11/03/09 Relevance Score: 67%

New Treatment Combination Promising for Children with Arthritis
MedLinePlus, 11/03/09 Relevance Score: 67%

Rituximab Therapy Produced Rapid and Sustained Clinical Improvement in a Patient With Systemic Onset Juvenile Idiopathic Arthritis Refractory to TNF Alpha Antagonists
Journal of Clinical Rheumatology (JCR), 10/09/09 Relevance Score: 67%

Analysis of quantitative ultrasound graphic trace and derived variables assessed at proximal phalanges of the hand in healthy subjects and in patients with cerebral palsy or juvenile idiopathic arthritis. A pilot study
Bone, 10/08/09 Relevance Score: 67%

Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis
Arthritis Care and Research, 11/02/09 Relevance Score: 66%